Experimental Hematology
Volume 35, Issue 4 , Pages 587-595 , April 2007

In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2V617F allele

  • Amos Gaikwad

      Affiliations

    • Department of Pediatric-Hematology Oncology, Baylor College of Medicine, Houston, Tex., USA
    • Texas Children's Cancer Center, Baylor College of Medicine, Houston, Tex., USA
    • ,
  • Roberto Nussenzveig

      Affiliations

    • Department of Leukemia, MD Anderson Cancer Center, Houston, Tex., USA
    • ,
  • Enli Liu

      Affiliations

    • Texas Children's Cancer Center, Baylor College of Medicine, Houston, Tex., USA
    • Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Tex., USA
    • ,
  • Stephen Gottshalk

      Affiliations

    • Department of Pediatric-Hematology Oncology, Baylor College of Medicine, Houston, Tex., USA
    • Department of Immunology, Baylor College of Medicine, Houston, Tex., USA
    • Texas Children's Cancer Center, Baylor College of Medicine, Houston, Tex., USA
    • Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Tex., USA
    • ,
  • KoTung Chang

      Affiliations

    • Division of Hematology, University of Utah, Salt Lake City, Utah, USA
    • ,
  • Josef T. Prchal

      Affiliations

    • Institute of Pathological Physiology, Charles University School of Medicine, Prague, Czech Republic
    • Division of Hematology, University of Utah, Salt Lake City, Utah, USA
    • Corresponding Author InformationOffprint requests to: Josef T. Prchal, M.D., School of Medicine, Hematology, University of Utah, Salt Lake City, UT 84124

Received 24 August 2006 ,Revised 20 December 2006 ,Accepted 20 December 2006.

References 

  1. Spivak JL. The chronic myeloproliferative disorders: clonality and clinical heterogeneity. Semin Hematol. 2004;41:1–5
  2. Najfeld V, Montella A, Scalise T, et al. Exploring polycythemia vera with fluorescence in situ hybridization: additional cryptic 9p is the most frequent abnormality detected. Br J Haematol. 2002;119:558–566
  3. Kralovics R, Guan Y, Prchal JT. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol. 2002;30:229–236
  4. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature. 2005;434:1144–1148
  5. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera. Cancer Cell. 2005;4:387–392
  6. Kralovics R, Passamonti F, Buser AS, et al. A gain of function mutation of JAK2 in myeloproloderative disorders. N Engl J Med. 2005;352:1779–1790
  7. Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem. 2005;280:22788–22792
  8. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–1061
  9. Baselga J, Arribas J. Treating cancer's kinase “addiction”. Nat Med. 2004;10:786–787
  10. Wadleigh M, DeAngelo DJ, Griffin JD, Stone RM. After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies. Blood. 2005;105:22–30
  11. Gaikwad A, Verstovsek S, Chang K, Yoon D, Vainchenker W, Prchal JT. Will imatinib be useful for patients with polycythemia vera?. Blood. 2005;106:2601
  12. Prchal J, Chang K, Jelinek J, et al. In vitro expansion of polycythemia vera progenitors favors expansion of erythroid precursors without JAK2 V617F mutation. Blood. 2005;106:3506
  13. Neildez-Nguyen TM, Wajcman H, Marden MC, et al. Human erythroid cells produced ex vivo at large scale differentiate into red blood cells in vivo. Nat Biotechnol. 2002;20:467–472
  14. Zhang J, Ma S, Gross AW, Lodish HF. Role of Ras signaling in erythroid differentiation of mouse fetal liver cells: functional analysis by a flow cytometry-based novel culture system. Blood. 2003;102:3938–3946
  15. Gottschalk S, Edwards OL, Sili U, et al. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood. 2003;101:1905–1912
  16. Nussenzveig R, Swierczek S, Jelinek J, et al. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol. 2007;35:32–38
  17. Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome–negative CML, and megakaryocytic leukemia. Blood. 2005;106:3370–3373
  18. Liu E, Jelinek J, Pastore Y, et al. Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. Blood. 2003;101:3294–3301
  19. Gaikwad A, Poblenz A, Haridas V, Zhang C, Duvic M, Gutterman J. Triterpenoid electrophiles (Avicins) suppress heat shock protein-70 and X-linked inhibitor of apoptosis proteins in malignant cells by activation of ubiquitin machinery: implications for proapoptotic activity. Clin Cancer Res. 2005;11:1953–1962
  20. Battle T, Frank D. The role of STATs in apoptosis. Curr Mol Med. 2002;2:381–392
  21. Kralovics R, Stockton DW, Prchal JT. Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood. 2003;102:3793–3796
  22. Tefferi A, Lasho TL, Gilliland G. JAK2 mutations in myeloproliferative disorders. N Engl J Med. 2005;353:1416–1417
  23. Petzer A, Eaves C, Barnett M, Eaves A. Selective expansion of primitive normal hematopoietic cells in cytokine-supplemented cultures of purified cells from patients with chronic myeloid leukemia. Blood. 1997;90:64–69
  24. Prchal JT. Polycythemia vera and other primary polycythemias. Curr Opin Hematol. 2005;12:112–116
  25. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol. 1997;9:10–16
  26. Silva M, Richard C, Benito A, Sanz C, Olalla I, Fernandez-Luna JL. Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N Engl J Med. 1998;338:564–571
  27. Ishii T, Bruno E, Hoffman R, Xu M. Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood. 2006;108:3128–3134
  28. Fisher MJ, Prchal JF, Prchal JT, D'Andrea AD. Anti-erythropoietin (EPO) receptor monoclonal antibodies distinguish EPO-dependent and EPO-independent erythroid progenitors in polycythemia vera. Blood. 1994;84:1982–1991

PII: S0301-472X(06)00763-6

doi: 10.1016/j.exphem.2006.12.007

Experimental Hematology
Volume 35, Issue 4 , Pages 587-595 , April 2007

Article Tools

* Image Usage & Resolution